Feasibility Assessments for Comparative Evidence Generation: Building on the Cope et al. (2014) Framework in the Era of EU JCA
How should feasibility assessments for indirect treatment comparisons evolve in the era of EU JCA? Our expanded framework builds on Cope et al. (2014) and adds five new domains.
Trends in 12-Month Mortality and Statutory Health Insurance Costs in Incident Metastatic Bladder Cancer in Germany, 2011–2024
In incident metastatic bladder cancer in Germany, costs per patient rose from €32,245 to €43,042 between 2011 and 2024, without any improvement in 12-month survival.
Rising Drug Costs With Stable 12-Month Survival in Incident Metastatic Breast Cancer in Germany, 2011–2024
In incident metastatic breast cancer in Germany, 12-month survival remained broadly stable from 2011 to 2024, while costs rose by 22.9%, driven by outpatient drugs.
Trends in 12-Month Mortality and Healthcare Costs in Incident Metastatic Colorectal Cancer in Germany, 2011–2024
In incident metastatic colorectal cancer in Germany, costs rose moderately (+17.2%) between 2011 and 2024 without a consistent improvement in 12-month survival.
Increasing Costs and Limited Mortality Improvement in Incident Metastatic Lung Cancer in German Statutory Health Insurance Claims, 2011–2024
Costs for incident metastatic lung cancer in Germany rose by 87.5% between 2011 and 2024, while 12-month survival improved only modestly and inconsistently.
More Than Doubling of Costs With Unchanged 12-Month Mortality in Incident Metastatic Prostate Cancer in Germany, 2011–2024
Costs per patient with incident metastatic prostate cancer in Germany more than doubled between 2011 and 2024 – while 12-month survival remained nearly unchanged.
Epidemiology, Clinical Burden and Inflammatory Marker Testing in Atherosclerotic Cardiovascular Disease and Symptomatic Heart Failure in Germany: Insights from the ACHILLES Claims Data Analysis
How large is the burden of atherosclerotic cardiovascular disease (ASCVD) and symptomatic heart failure (HF) in Germany today – and how often is inflammation actually tested in routine care?
The ACHILLES claims data analysis, based on GWQ ServicePlus data from approximately 7.8 million individuals (2020–2024), identified 173,327 incident ASCVD and 121,208 incident symptomatic HF patients. In 2023, the age- and sex-adjusted incidence was 779 (ASCVD) and 668 (HF) per 100,000 individuals. Within 24 months, one in three ASCVD patients and almost one in two HF patients had a CV-related hospitalization – yet CRP testing was observed in only about 40% of patients in the first year after diagnosis.